Shanghai RAAS executives complete share increase, exceeding target

Shanghai RAAS Blood Products announced the completion of its share increase plan by some directors and all senior management. Between September 10, 2025, and October 30, 2025, participating executives acquired a total of 946,000 shares through centralized bidding, representing 0.014% of the company's total share capital. The aggregate investment amounted to 6,482,799.40 yuan, surpassing the original target of no less than 6 million yuan.

The share increase plan, initially disclosed on September 5, 2025, aimed to bolster investor confidence, reflecting the executives' belief in the company's "plasma collection and fractionation" strategic development and long-term investment potential. Notably, vice chairman and general manager Jun Xu increased his holdings by 727,900 shares, bringing his total to 1,946,100 shares, or 0.029% of the company's total share capital, with an investment of 5,000,673 yuan.

The company confirmed that this share increase aligns with relevant laws and regulations, will not alter the company's equity structure or control, and is not expected to affect its governance or ongoing operations. All participating executives have committed to not reducing their holdings during the statutory lock-up period and will comply with all transfer regulations in the future.